Corrigendum to ‟Repurposing FDA-approved drugs to fight COVID-19 using in silico methods: Targeting SARS-CoV-2 RdRp enzyme and host cell receptors (ACE2, CD147) through virtual screening and molecular dynamic simulationsˮ [Inform. Med. Unlocked 23 (2021) 1-9/100541]

• Soodeh Mahdian,
• Mahboobeh Zarrabi,
• Yunes Panahi,
• Somayyeh Dabbagh Sadeghpour

Affiliations

Soodeh Mahdian

Department of Cellular and Molecular Biology, Faculty of Biological Sciences, North Tehran Branch, Islamic Azad University, Tehran, Iran

Mahboobeh Zarrabi

Department of Biotechnology, Faculty of Biological Sciences, Alzahra University, Tehran, Iran; Corresponding author.

Yunes Panahi

Pharmacotherapy Department, Faculty of Pharmacy, Baqiyatallah University of Medical Sciences, Tehran, Iran

Somayyeh Dabbagh Sadeghpour

Department of Biotechnology, Faculty of Biological Sciences, Alzahra University, Tehran, Iran